New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
11:20 EDTEXEL, RHHBYExelixis seen as potential target for Roche, TheStreet says
David Miller thinks Roche (RHHBY) will likely acquire Exelixis (EXEL) after the partners announced a phase III study of coBRIM in melanoma met its primary endpoint, reported TheStreet's Adam Feuerstein. Shares of Exelixis are up nearly 8% following this morning report on the trial. Reference Link
News For EXEL;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
07:39 EDTRHHBYAbbVie says venetoclax granted Breakthrough Therapy Designation by FDA
Subscribe for More Information
May 5, 2015
16:15 EDTRHHBYPacific Biosciences achieves second development milestone under Roche pact
Subscribe for More Information
May 4, 2015
07:26 EDTRHHBYWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
May 1, 2015
07:43 EDTRHHBYExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
16:41 EDTEXELExelixis sees first six months operating expenses $70M-$80M
Subscribe for More Information
16:40 EDTEXELExelixis reports Q1 EPS (18c), consensus (24c)
Reports Q1 revenue $9.39M, consensus $8.08M.
April 27, 2015
06:19 EDTRHHBYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use